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A B S T R A C T
Aneuploidy, the unbalanced state of the chromosome content, represents a hallmark of most solid tumors, in-
cluding colorectal cancer. Such aneuploidies result in tumor specific genomic imbalances, which emerge in
premalignant precursor lesions. Moreover, increasing levels of chromosomal instability have been observed in
adenocarcinomas and are maintained in distant metastases. A number of studies have systematically integrated
copy number alterations with gene expression changes in primary carcinomas, cell lines, and experimental
models of aneuploidy. In fact, chromosomal aneuploidies target a number of genes conferring a selective ad-
vantage for the metabolism of the cancer cell. Copy number alterations not only have a positive correlation with
expression changes of the majority of genes on the altered genomic segment, but also have effects on the
transcriptional levels of genes genome-wide. Finally, copy number alterations have been associated with disease
outcome; nevertheless, the translational applicability in clinical practice requires further studies. Here, we (i)
review the spectrum of genetic alterations that lead to colorectal cancer, (ii) describe the most frequent copy
number alterations at different stages of colorectal carcinogenesis, (iii) exemplify their positive correlation with
gene expression levels, and (iv) discuss copy number alterations that are potentially involved in disease outcome
of individual patients.
1. Introduction to colorectal cancer genetics
1.1. Milestones in the genetic characterization of colorectal cancer
Cancer, colorectal cancer (CRC) included, is a disease marked by the
aberrant behavior of cells that invade and destruct pre-existing tissues,
both locally in the organ of origin and at a distance, i.e., metastatic
sites. This selfish cell growth, and altered metabolic processes asso-
ciated with it, can be lethal, despite of medical interventions. The
aberrant behavior of tumor cells is driven by alterations in cell biology
and affects critical processes such as proliferation, invasion, evasion to
cellular death, and escape to immune surveillance, i.e., the so-called
hallmarks of cancer (Hanahan and Weinberg, 2011). These alterations
in cell biology, in turn, are the result of an evolutionary process by
which gene mutations and somatically acquired copy number altera-
tions (CNAs) accumulate and result in the selective advantage of cells
that carry these alterations. The accumulation of genetic damage results
in the expansion of initially benign (i.e., non-invasive) tumors, which,
when untreated, form invasive subclones and lead to cancer. DNA al-
terations come in many flavors, namely, small nucleotide variants
(SNVs), small insertions or deletions (Indels), structural variants (SVs)
or epigenetic alterations, mostly promoter hypermethylation, and in
chromosomal copy number alterations, i.e., aneuploidy. The role of
chromosomal aneuploidy in tumorigenesis was for a long time under-
estimated despite observations by Hansemann in the 19th century
(Hansemann, 1890), and work by Theodor Boveri in the 1920s
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(reviewed in Ried, 2009). In fact, in several hematological neoplasia
and soft tissue tumors, specific chromosomal rearrangements had been
found to be pathogenic (Rabbitts, 1994). Karyotyping of metaphases
from tumor cells had been key to these observations, and this approach
worked well in leukemias and soft tissue tumors, describing single or
few chromosome rearrangements resulting in fusion genes (Heim and
Mitelman, 2015). However, the role of specific chromosomal changes in
the origin of solid tumors like CRC was harder to establish, mainly at-
tributable to very complex and highly rearranged karyotypes. Yet, using
methods like DNA flow cytometry and DNA image cytometry it had
been clearly established that most CRCs showed abnormal nuclear DNA
content, for which chromosomal copy number changes can be the only
explanation (Giaretti et al., 2004; Steinbeck et al., 1994, 1993).
Groundbreaking work from Vogelstein and collaborators early in
the 90's has shown that the accumulation of alterations in genes in-
volved in key signaling pathways led to the neoplastic alteration of
normal colonic epithelial cells, ultimately transforming into cancer
(Fearon and Vogelstein, 1990). Accordingly, an early crucial event in
the development of CRC is the disruption of the WNT-signaling
pathway, leading to the formation of an adenoma, and this occurs in the
majority of cases by disruption of the APC gene, either by truncating
mutations or, less frequently, by loss of the long arm of chromosome 5
(5q), where APC is located. Subsequent accumulation of mutations in
KRAS involved in the MAPK signaling pathway, losses on the long arm
of chromosome 18, affecting TGF-β signaling pathway, and mutations
in TP53 or loss of the short arm of chromosome 17 (17p), where TP53 is
located, result in the formation of cancer (Fearon and Vogelstein,
1990).
With the introduction of comparative genomic hybridization (CGH)
(du Manoir et al., 1993; Kallioniemi et al., 1992) and, later on, mi-
croarray CGH (array CGH) (Pinkel et al., 1998), it became possible to
analyze CNAs genome-wide in one single experiment without the need
for metaphase chromosome preparations from dividing cells. These
molecular cytogenetic analyses confirmed and refined results estab-
lished using conventional karyotype analysis (Bardi et al., 1993, 1991).
This led to thorough characterization of non-random CNAs observed in
microsatellite stable CRC, mainly gains of chromosomes 7, 8q, 13, and
20q as well as losses of 8p, 17p, and 18 (Camps et al., 2006; Douglas
et al., 2004; Meijer et al., 1998; Nakao et al., 2004; Ried et al., 1996)
Together with SNVs and CNAs, other alterations at the DNA or epi-
genome level turned out to be important as well. CpG island promoter
methylation is a relevant mechanism for silencing gene expression
(Baylin and Herman, 2000) and it is suggested to precede CNAs in the
development of some CRC (Derks et al., 2006). In 2012, The Cancer
Genome Atlas Network (TCGA) comprehensively characterized 276
CRCs at mutation, DNA copy number, hypermethylation and expression
levels (Cancer Genome Atlas Network, 2012). They confirmed pre-
viously well-defined CNAs, including 1q, 7, 8q, 13q, and 20q gains and
1p, 4, 5q, 8p, 14q, 15q, 17p, and 18q losses as being frequently ob-
served in CRC. These CNAs frequently co-occur within the same tumor,
indicating potential interaction between loci within these chromosomes
leading to a selective advantage (Hermsen et al., 2002; Takahashi et al.,
2015).
1.2. Patho-biological classification of colorectal cancer
There are many ways in which CRCs can be patho-biologically
classified. Two main genomic instability pathways are observed in CRC,
the chromosomal instability (CIN) pathway, occurring in 85% of the
cases, and the microsatellite instability (MSI) pathway, occurring in
15% of the cases (Lengauer et al., 1998). CIN CRCs are characterized by
gross chromosomal aberrations (numerical and structural) while MSI
CRCs are characterized by mutations at single nucleotide level in re-
petitive regions (microsatellites) resulting from a deficiency in the DNA
mismatch repair mechanism (Boland and Goel, 2010).
CRCs can also be classified according to the levels of promoter
hypermethylation (CpG Island Methylator Phenotype; CIMP), being
divided in CIMP-high and CIMP-low CRCs (Toyota et al., 1999). There
is a strong association of MSI phenotype with CIMP, due to hy-
permethylation of the mismatch repair gene hMLH1 (Cancer Genome
Atlas Network, 2012). Another classification based on the tran-
scriptome has been put forward, including four different subtypes of
CRC (Guinney et al., 2015). These Consensus Molecular Subtypes
(CMS), however, are not completely discrete classes as there is some
degree of overlap, reflecting a continuity of CRC transcriptomes (Ma
et al., 2018). With the exception of CMS1 (MSI CRCs), all other 3 CMS
groups (CMS2-4) present to a certain extent higher/lower degree of
CNAs (CIN CRCs) (Guinney et al., 2015). Translation of CMS classifi-
cation to preclinical models and clinical practice uncovered potential
for targeted treatment (Sveen et al., 2018).
2. Temporal acquisition of CNAs throughout colorectal
tumorigenesis
2.1. Adenoma to carcinoma progression
The disruption of the WNT-signaling pathway and the acquisition of
chromosomal aneuploidy (e.g., extra copy of chromosome 7) might
result in the formation of an adenoma, which progresses towards car-
cinoma through the accumulation of additional (epi)-genetic alterations
in a background of genomic instability (Fearon and Vogelstein, 1990).
Different precursor lesions, with different morphology, can lead to the
development of CRC. These can be conventional (polypoid or flat)
adenomas or sessile serrated polyps. Although the total amount of CNAs
in advanced adenomas is low compared to carcinomas, the presence of
chromosomal aneuploidies and genomic alterations in such pre-
malignant lesions needs to be considered, contributing to the acquisi-
tion of relatively high levels of genetic heterogeneity (Cross et al.,
2018). Furthermore, differences in the patterns of CNAs can be ob-
served between different morphologies, namely, polypoid adenomas
and non-polypoid adenomas. In a comparison of a large series of non-
polypoid adenomas with polypoid adenomas, it was shown that non-
polypoid adenomas more frequently presented 5q losses, but less 1p,
10q, 17p and 18q losses than polypoid adenomas (Voorham et al.,
2012). Other precursors, such as sessile serrated polyps (IJspeert et al.,
2015), progress to cancer via the MSI pathway, and therefore do not
show the common CNAs observed in tumors arising via the CIN
pathway (Bettington et al., 2017; Casorzo et al., 2015; Gaiser et al.,
2013).
2.2. DNA copy number alterations associated with progression
Despite the fact that chromosomal aneuploidies can be observed in
premalignant lesions, their appearance is more frequent in later stages
during the transition to malignancy (Matano et al., 2015; Saito et al.,
2018). Several studies showed that specific CNAs were associated with
such transition (Hermsen et al., 2002; Meijer et al., 1998; Ried et al.,
1996). It has been demonstrated that in adenomas in which a carci-
noma is present (so-called progressed adenomas), the phenotypically
benign part already contains most chromosomal aberrations present in
the cancer, indicating a role of these aberrations, namely gains of 8q,
13q and 20q, and losses of 8p, 15q, 17p and 18q, in the adenoma-to-
carcinoma progression (Carvalho et al., 2009; Hermsen et al., 2002)
(Fig. 1). The presence of two or more of these CNAs has an accuracy of
80% for predicting the risk of an adenoma to progress to cancer
(Hermsen et al., 2002). Moreover, studies modelling colorectal ade-
noma-to-carcinoma progression by perturbing organoids with gene
mutations have shown that only organoids derived from adenomas with
CNAs were able to form invasive tumors in mice, indicating the im-
portance of these alterations (Drost et al., 2015; Matano et al., 2015).
Genomic imbalances in distant metastases (e.g., liver) are of high si-
milarity as those already present in the adenocarcinoma (Haan et al.,
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2014; Platzer et al., 2002; Xie et al., 2014). Altogether, these studies
show the significance of CNAs with respect to the progression from
colorectal adenomas to cancer.
2.3. High-risk adenoma versus advanced adenoma
Colorectal adenomas are a very common finding in elderly people
with a prevalence of 18–35% reported in screening series (Imperiale
et al., 2000; Lieberman et al., 2000). However, it is thought that only
about 5% of colonic polyps removed at the time of endoscopy would
have progressed to cancer (Shinya and Wolff, 1979). Indeed, histo-
pathological features associated with the presence of focal cancer in
adenomas include size ≥10mm, high-grade dysplasia and villous his-
tology (Muto et al., 1975; Shinya and Wolff, 1979). The presence of at
least one of these histopathological features led to the concept of ad-
vanced adenoma (Winawer et al., 1993). However, the accuracy of
these features to identify advanced adenomas that would be at risk to
progress to cancer is low. Nonetheless, advanced adenomas are used in
screening and surveillance programs as intermediate endpoints for CRC
death. In a study evaluating the long-term effect of adenoma removal
on reduction of CRC mortality, only a moderate effect was observed
when advanced adenomas were removed (Løberg et al., 2014). This
indicates that the use of advanced adenomas as intermediate endpoints
associated with disease progression, leads to an overestimation of risk
of dying from CRC, which translates to overdiagnosis. There is need for
new intermediate endpoints that more precisely reflect the natural
course of the disease, and more specifically identify adenomas at high
risk of progressing to cancer (Sillars-Hardebol et al., 2012). In a recent
pilot study, it has been shown that only 25% of advanced adenomas
showed DNA CNAs associated with progression and that 2–4% of non-
advanced adenomas already show these aberrations (Carvalho et al.,
2018). This indicates that CNAs associated with progression from
adenoma to cancer could more accurately identify adenomas at risk and
therefore perform better as intermediate endpoints in CRC screening
and surveillance programs.
3. Comprehensive assessment of copy number alterations
3.1. Experimental strategies to analyze copy number alterations in cancer
Beyond conventional G-banding, molecular cytogenetic techniques,
including FISH-related approaches (Cremer et al., 1988, 1986; Pinkel
et al., 1988; Ried et al., 1992; Schröck et al., 1996; Speicher et al.,
1996) and conventional and array CGH (du Manoir et al., 1993;
Kallioniemi et al., 1992, 1992; Pinkel et al., 1998), improved the ana-
lysis of chromosome aberrations in both hematological and solid
tumors. CGH allowed mapping of genomic imbalances in solid tumors
to an unprecedented level by comparing the genomic DNA extracted
from the tumor sample with a reference genome without the require-
ment of metaphase chromosome preparations. This allowed the use of
formalin-fixed and paraffin embedded material for cytogenetic analyses
(Ried et al., 1995; Speicher et al., 1993). The application of CGH pro-
vided evidence that genomic imbalances were responsible for tumor
progression from dysplastic lesions to invasive disease (Heselmeyer
et al., 1996). Later on, single nucleotide polymorphism (SNP)-based
DNA microarrays allowed simultaneous measurement of the allele-
specific copy number at many different single nucleotide polymorphic
loci in the genome, thus resulting in a high resolution detection of LOH,
a common event in tumorigenesis, in addition to the identification of
CNAs at a resolution similar to that of array CGH (Beroukhim et al.,
2006; Heinrichs and Look, 2007; Mullighan et al., 2007). This tech-
nology also allowed the identification of copy neutral LOH, a common
feature affecting cancer, including colorectal (Torabi et al., 2019, 2015;
Tuna et al., 2009).
3.2. Novel methodologies to assess copy number alterations based on next-
generation sequencing
Besides array CGH and SNP-arrays, the development of massive
parallel sequencing through next-generation sequencing platforms led
to the development of many tools to infer CNAs from whole-exome
(WES) and whole-genome sequencing (WGS). Consensus “best-prac-
tices” workflow for short-reads sequencing management has been
possible, in part, due to the Genome Analysis Toolkit (GATK) (McKenna
et al., 2010). In addition, many other calling tools have been included
in the omicX database (https://omictools.com) (Henry et al., 2014),
some of the most relevant being listed in Table 1. Four computational
approaches to handle genomic sequencing have been described to de-
tect structural variants of the genome: (i) read pair, which compares
distances between mapped paired reads and average insert size of the
genomic library; (ii) split read, to detect small insertions and deletions
through analyzing alignment to the reference genome, taking special
attention to continuous stretches of gaps in the reads; (iii) assembly
methods, where reference-free reconstruction of the entire genome from
a collection of reads is computed and compared to the reference
genome by applying multiple software; and (iv) read count or depth of
coverage, the most recent approach, which takes into account the
number of reads mapping for each region in the genome and assuming
uniform sequencing process, so the number of reads in a specific region
would be proportional to its copy number (Magi et al., 2017; Yoon
et al., 2009). Recent studies have attempted to benchmark and evaluate
the performance of several methods, further emphasizing differences
Fig. 1. Genomic alterations associated with the histopathological sequence of colorectal tumorigenesis. As shown, while APCmutation is present in most low-
grade adenomas, chromosomal aneuploidies affecting chromosomes 7, 13 and 20q occur prior the transition from adenoma to adenocarcinoma. As indicated,
additional genomic imbalances and single nucleotide variants result in the formation of the infiltrating adenocarcinoma providing the invasive phenotype.
Histological sections are representative images stained with hematoxylin and eosin.
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between tools despite the common usage of a calling method for data
segmentation (Alkodsi et al., 2015; Kadalayil et al., 2015; Liu et al.,
2013; Nam et al., 2016; Trost et al., 2018; Zare et al., 2017). Tools such
as GISTIC2.0 (Mermel et al., 2011), ConVaQ (Larsen et al., 2018) or
CNApp (Franch-Exposito et al., 2018) allow cohort-level studies to in-
tegrate genomic CNA data with additional molecular and clinical fea-
tures, and unravel new functional implications for these genomic
events.
3.3. Copy number alteration signatures
To a certain extent, cancer genome SNVs and CNAs delineate the
track of unrepaired genetic alterations that have accumulated during
the lifetime of the tumor. In this sense, studies of SNV signatures
identified mutational patterns originated by different types of nucleo-
tide changes in a given tumor type, defined as mutational signatures
(Alexandrov et al., 2013; Nesic et al., 2018). In contrast to SNVs, only
the calling for the presence or absence of a chromosome alteration in
tumor cells, but not the underlying mechanisms of such patterns, are
described. Therefore, efforts to identify copy number signatures have
been made considering different approaches and accounting for diverse
features. By applying non-negative matrix factorization models to 32
rearrangement subclasses in whole genome sequencing derived breast
cancer data, six rearrangement signatures based on their association
with homologous recombination deficiency and microhomology-medi-
ated end joining mechanisms were extracted (Nik-Zainal et al., 2016).
Likewise, eight copy number signatures based on structural features
obtained from copy number profiles were identified by using low-pass
whole genome sequencing in high-grade serous ovarian cancer
(Macintyre et al., 2018). These authors correlated CNA signatures with
prognosis and response to treatment, suggesting their utility as clinical
biomarkers. Finally, pan-cancer studies unraveled nine signatures re-
sponsible for the etiology of structural variants, suggesting that re-
plication-based mechanisms generated varying chromosomal structures
with low-level copy number gains and frequent inverted rearrange-
ments across different tumor types, including CRC (Camps et al., 2008;
Li et al., 2017).
4. Transcriptional consequences of copy number alterations
4.1. Positive correlation between copy number alterations and expression
levels
It has been firmly established that CNAs are specific to the tissue of
cancer origin, thus reflecting specific landscapes of genomic imbalances
for each tumor type (Beroukhim et al., 2010; Ried et al., 2012). As
mentioned earlier, in colorectal carcinomas, tumorigenesis requires
specific CNAs, e.g., gains of chromosomes 7, 8q, 13, and 20q, and losses
of 8p, 17p, and 18. Such observations trigger the question what are the
consequences of these so dominantly selected aneuploidies with respect
to the transcription levels of genes on the affected chromosomes. In
fact, among several hypotheses as to why transcriptional programs are
affected by arm-level and whole chromosome-level CNAs, the body of
literature indicates that CNAs directly affect the expression of the ma-
jority of genes on the altered genomic segment; however, the extent to
which genes other than oncogenes and tumor suppressors contribute to
malignant transformation or maintenance of the transformed state re-
mains unclear. The biological consequence of chromosomal aneuploidy
is not limited to the affected chromosomal region, but may be due to
effects on the transcriptional activity of genes residing in other areas of
the genome. Naturally, a third possibility is that chromosomal aneu-
ploidies only target a small or limited number of genes conferring a
selective advantage for the metabolism of the cancer cell.
Cell lines derived from primary carcinomas have been extensively
used to measure the effect of genomic CNAs on the expression of re-
sident genes. Analysis of 15 CRC cell lines, including mismatch repair
proficient and deficient lines, showed positive genome-wide correlation
between CNAs determined by array CGH and corresponding average
gene expression (Camps et al., 2009). Such correlations have been
confirmed in many other tumor types. For example, Wolf and collea-
gues arrived at the conclusion that a correlation between copy number
with gene expression levels became evident genome-wide in prostate
cancer cell lines (Wolf et al., 2004). Using the NCI-60 cancer cell line
panel, a correlation between gene expression and copy number for all
genes showed an overall medium high correlation, with significantly
higher correlations for the known tumor suppressor genes (Varma et al.,
2014). Recently, Tao and colleagues reported that gene up-regulation
or down-regulation is significantly correlated with genomic amplifica-
tion or deletion events in a set of six cervical cancer cell lines (Yan
et al., 2017).
The correlation of genomic copy number and average gene ex-
pression levels also applies to primary tumors. In fact, several authors
have shown the influence of canonical arm and chromosome-level
CNAs on gene expression levels in pre-malignant lesions and carci-
nomas of different origin (Camps et al., 2008; Carvalho et al., 2009;
Fehrmann et al., 2015; Grade et al., 2007, 2006; Ortiz-Estevez et al.,
2011; Pollack et al., 2002) (Fig. 2). In this set of studies, the authors
have explored several cohorts of colon and rectal cancer samples and
matched normal mucosa, and identified that upregulation of genes was
highest for those located on chromosomes 7, 13 and 20, i.e., chromo-
somes that are consistently gained, while downregulated genes were
consistently located at chromosome 18, and to a lesser extent, at
Table 1
Computational tools and methods for detection of CNAs detection in massive sequencing platforms.
Name Sequencing platform Implementation Programming language Link Reference
CNVkit WES/WGS Software Python https://cnvkit.readthedocs.io/en/stable/index.html Talevich et al. (2016)
ExomeDepth WES CRAN package R https://cran.r-project.org/web/packages/
ExomeDepth/index.html
Plagnol et al. (2012)
VarScan2 WES/WGS Command-line software Java http://dkoboldt.github.io/varscan/ Koboldt et al. (2012)
ControlFreeC WES/WGS Software C++ http://boevalab.com/FREEC/ Boeva et al. (2011)
ExomeCNV WES CRAN package R https://cran.r-project.org/src/contrib/Archive/
ExomeCNV/
Sathirapongsasuti et al. (2011)
XHMM WES Software C++ https://atgu.mgh.harvard.edu/xhmm/index.shtml Fromer et al. (2012)
CoNIFER WES Command-line software Python http://conifer.sourceforge.net/index.html Krumm et al. (2012)
Delly WGS Software C++ https://tobiasrausch.com/delly/ Rausch et al. (2012)
XCAVATOR WGS Software Perl, bash, R, Fortran http://sourceforge.net/projects/xcavator/ Magi et al. (2017)
CNVnator WGS Software C++ http://sv.gersteinlab.org/cnvnator Abyzov et al. (2011)
CNV-seq WGS Package R, perl http://tiger.dbs.nus.edu.sg/cnv-seq/ Xie and Tammi (2009)
Pindel WGS Command-line software C++ http://gmt.genome.wustl.edu/packages/pindel/
quick-start.html
Ye et al. (2009)
CONTRA WES Software Python/R http://contra-cnv.sourceforge.net Li et al. (2012)
WES, whole-exome sequencing; WGS, whole-genome sequencing.
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chromosomes 14 and 15, which are usually lost in CRC. By assessing the
expression levels of normal colon epithelium, adenomas, carcinomas of
different stages, and metastasis two independent studies provided fur-
ther evidence of a copy number dependent transcriptional deregulation
(Habermann et al., 2007; Tsafrir et al., 2006). Additionally, Sheffer and
colleagues convincingly demonstrated that the pattern of gene expres-
sion profiles alone is sufficient to predict genomic CNAs in a compre-
hensive dataset of colorectal carcinomas (Sheffer et al., 2009). Re-
cently, data derived from whole-genome sequencing and reported by
The Cancer Genome Atlas consortium was used to map somatic struc-
tural changes, including CNAs, in 600 tumors of diverse origins,
showing their contribution to altered gene expression in human cancer
(Alaei-Mahabadi et al., 2016).
A gene-oriented assessment of such positive correlation between
CNAs and gene expression has resulted in the discovery of novel cancer-
related genes. In particular, in CRC, the gain of chromosome 13 and
their associated overexpression of numerous genes, provided a unique
chance to uncover several genes associated with tumorigenesis.
Notably, these gene-dosage transcriptional dependent genes were
mostly located at the proximal cytoband 13q12.12-q12.2. This included
CDK8, CDX2, and LNX2, for which the overexpression was associated
with WNT-pathway activity and tumorigenic features (Camps et al.,
2013; Firestein et al., 2008; Salari et al., 2012). Similarly, but in a more
distal region of the same chromosome, DIS3, KLF5, IRS2, and miRNA
family miR17-92 were also chromosome 13 located cancer-related
genes (Camps et al., 2003; Day et al., 2013; de Groen et al., 2014;
Diosdado et al., 2009; Le et al., 2015). Besides overexpression of genes
on chromosomes usually involved in recurrent CNAs, other regions of
CRC genomes eventually involved in genomic imbalances do as well
contain genes whose expression is correlated with gene dosage, such as
the amplification and consequent overexpression of IGF2 at 11p15.1
(Cancer Genome Atlas Network, 2012). Furthermore, an amplicon
present in> 70% of colorectal tumor samples at 20q11-20q13 con-
tained several cancer-related genes (AHCY, POFUT1, RPN2, TH1L, and
PRPF6) that were upregulated and showed a significant linear corre-
lation for gene dosage and gene expression (Loo et al., 2013). Also,
TPX2 (20q11.21) and AURKA (20q13.2), overexpressed as a con-
sequence of gene-dosage, were shown to play a functional role as on-
cogenes driving this amplicon (Sillars-Hardebol et al., 2012). Similarly,
copy number loss at 8p, a CNA associated with colorectal adenocarci-
noma and poor prognosis, was observed in>50% of the tumor samples
and demonstrated a significant linear correlation for two potential
tumor suppressor genes, MTUS1 (8p22) and PPP2CB (8p12) (Loo et al.,
2013). Additionally, focal deletions at 6q25-q27 reducing the
expression of PARK2 have been associated with APC deficiency in CRC
(Poulogiannis et al., 2010b). Other integrative studies in CRC revealed
that the genes ARGLU1, UGGT2, CES2, FUT10, and PAOX were the top
five correlated genes in a set of 15 paired tumor-normal samples (Ali
Hassan et al., 2014).
4.2. Model systems to study aneuploidy-dependent changes in the
transcriptome
In order to study the impact of CNAs on gene expression, several cell
line or animal models have been developed. Despite the technical dif-
ficulties on generating stable models of aneuploidy, several groups have
addressed the physiological and functional effects of aneuploidy-de-
pendent transcriptional deregulation in model systems, such as cell
lines (Habermann et al., 2007; Nawata et al., 2011; Stingele et al., 2012;
Upender et al., 2004; Wangsa et al., 2019), budding yeast (Torres et al.,
2007), and mouse models (Williams et al., 2008). These and other
studies have further revealed that CNAs affect the expression not only
of the genes located on the aneuploid chromosome, but also of multiple
other genes across the entire genome, which influence protein expres-
sion as well (Gemoll et al., 2013; Sheltzer et al., 2012). This massive
transcriptional deregulation triggers cellular pathways associated with
environmental stress response, which at least in yeast, seems to be re-
lated to the aneuploidy-driven slow growth (Donnelly and Storchová,
2014; Torres et al., 2007). In addition, cellular responses similar to
those observed in artificially induced trisomic cells are related to pro-
teotoxic stress, most likely due to the increased amount of the protein
load in the cell, which may induce autophagy (Chunduri and Storchová,
2019). Furthermore, at the physiological level several model systems
have suggested compromised growth as a consequence of induced an-
euploidy, leading to the hypothesis that single-chromosome gains can
suppress transformation in newly generated trisomies; however, after
cellular progression and associated genome destabilization, the same
study showed that evolved complex karyotypes contributed to the ag-
gressive growth of advanced malignancies (Sheltzer et al., 2017).
5. CNAs as biomarkers for clinical outcome
5.1. Association of CNAs with clinical-histological features and outcome
Only a few genetic biomarkers are currently used in clinical deci-
sions related to CRC. These include RAS mutation, which is used rou-
tinely in CRC patients to guide the administration of anti-EGFR therapy.
Similarly, the BRAF V600E mutation is a biomarker of poor prognosis in
Fig. 2. Diagram depicting the positive correlation between genomic copy number alterations and levels of gene expression. The presence of an extra
chromosome 7 results in the upregulation of most of the genes in this chromosome. Filled circles indicate genes that are considered over- (in blue) and under-
expressed (in red) (middle panel) (adapted from Upender et al., 2004). Positive correlation between array CGH and gene expression for genes on chromosome 7 has
been established for a set of 18 patients with colorectal cancer (R= 0.949) (right panel) (data source from Camps et al., 2013). (For interpretation of the references to
color in this figure legend, the reader is referred to the Web version of this article.)
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patients with metastatic CRC (mCRC) (Yokota et al., 2011). Another
prognostic marker used in the clinic, albeit it is only listed as a re-
commendation in the clinical guidelines, is the mismatch repair status
(Sepulveda et al., 2017). Additionally, this guideline concluded that
there was insufficient evidence to recommend the following as pre-
dictive biomarkers in CRC outside of clinical trials: BRAF V600E mu-
tation, PIK3CA mutational analysis and PTEN expression or deletion
(Sepulveda et al., 2017).
To date, there are still unmet clinical needs in certain areas of CRC
management, notably for prognostication in stage II colon cancer pa-
tients, who suffer from a lack of effective stratification parameters to
inform who are most likely to recur (Dimitriou et al., 2018). In fact, the
majority of current predictive biomarkers are only applied to stage IV
CRC patients. Thus, many patients would benefit from improved
prognostic and predictive stratification, which would also help with
clinical trial design, for example in basket trials. CRC still lacks ade-
quate predictive biomarkers compared to other cancers such as mela-
noma, leukemia, breast, ovarian, prostate and lung cancer (Sameek and
Chinnaiyan, 2014). As molecular cytogenetic methodologies as well as
next-generation sequencing-based techniques to assess CNAs can be
applied to archived formalin-fixed paraffin-embedded (FFPE) material,
the analysis of large series of CRCs with well annotated clinical follow-
up became feasible allowing the analysis of the prognostic and pre-
dictive value of CNAs. Therefore, CNAs affecting genes such as SMAD2,
MYC, EGFR, STRAP, SMAD7, and SMAD4 are being investigated for
prognostic or predictive significance (Briffa et al., 2015; Hu et al., 2018;
Postma et al., 2009). Another study on the effect of CNAs in several
cancers highlighted their effect on proliferation and glycolysis (Graham
et al., 2017). Despite the fact that several studies have been published
on the prognostic and predictive values of CNAs in CRC, in this review
we have limited our discussion to non-controversial candidate bio-
markers that have been investigated in prospective clinical trials. The
candidate biomarkers with their corresponding clinical relevance are
summarized in Table 2.
5.2. Prognostic biomarkers
In advanced CRC, increased EGFR copy number is associated with
poor survival and might be an independent prognostic variable (Lenz
et al., 2006). With regard to PTEN, the Molecular Biomarkers Guideline
for the Evaluation of Colorectal Cancer states that more rigorous studies
are required for PTEN deletion to be accepted as a prognostic/pre-
dictive biomarker in CRC (Sepulveda et al., 2017). STRAP amplification
was reported in 22.8% of stage II and III CRC (n=166) (Buess et al.,
2004a). This gene is located on chromosome 12 and encodes a serine/
threonine kinase receptor associated protein. Of interest, patients that
did not receive adjuvant therapy (n= 95) showed better prognosis
when STRAP was amplified. In another cohort of 354 CRC patients
(stage IV, n=240), both gain and amplification of chromosome 20q
were associated with longer overall survival (OS) in mCRC patients.
Amplification was observed in 7% of mCRCs, while chromosome 20q
copy number gains were observed in 37% of mCRC patients. This
chromosome arm harbors several CRC-related oncogenes that might
explain its prognostic value, including SRC, AURKA, TPX2, and BCL2L1
(Ptashkin et al., 2017). The authors concluded that chromosome 20q
gain/amplification is an early tumorigenic event and that it is involved
with distant metastases.
Another chromosome of interest in CRC is chromosome 18q, and its
deletion is postulated to be a biomarker of poor prognosis (Storojeva
et al., 2005). Deletion of CD226, a gene located on chromosome 18q
that encodes for a glycoprotein expressed on the surface of NK cells,
platelets, monocytes and a subset of T-cells, has been shown to be a
biomarker of poor prognosis for 5-year OS and disease-free survival
(DFS) (n=94) (Ptashkin et al., 2017; Wagner et al., 2017). In the same
CRC cohort (n= 97), deletion of CDH-7 copy number was a biomarker
of good outcome with respect to 5-year OS and DFS. On the contrary, inTa
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a cohort of 147 patients, SMAD4 copy number loss was detected in
34.7% of Chinese CRC patients, was more frequent in mCRC compared
to early stage CRC, and was associated with tumor progression (Ma
et al., 2014). Boulay and colleagues reported that SMAD7 was deleted
in 43% of the 264 CRC cases and amplified in 15%. In this study, pa-
tients having SMAD7 deletion had a statistically significant better OS
and progression free survival (PFS). On the other hand, SMAD7 am-
plification was associated with a worse OS and PFS. The authors
speculated that on the assumption that SMAD7 regulates TGFβ sig-
naling, copy number amplifications antagonize cell growth arrest and
apoptosis (Boulay et al., 2003). Similarly, a multivariate analysis
identified the loss of BRUNOL4 located at 18q12.2 as an independent
factor associated with poor prognosis in CRC (Poulogiannis et al.,
2010a).
Recently, Lee and colleagues showed that GAEC1 (gene amplified in
esophageal cancer 1), a putative oncogene located on chromosome 7
was amplified in 24.1% of the Australian CRC cohort (n= 79) (Lee
et al., 2018). Moreover, copy number gain was associated with worse
prognosis due to increased tumor aggressiveness. Another prognostic
CNA is SKI, located on chromosome 1 and a repressor of TGF-β sig-
naling. In a cohort of 533 stage II and III CRC cases, SKI gene copy
number could be successfully measured in 159 patients and was am-
plified in 10.1% (Buess et al., 2004b). SKI amplification was associated
with a worse OS and DFS as compared to patients with no copy number
increase or deletions of this gene.
In 2002, a study on an early-stage CRC cohort (n=180) in-
vestigated allelic imbalance of chromosomes 8p and 18q with respect to
disease recurrence. Patients with Dukes' A stage tumors showing allelic
imbalance in both chromosome arms were more likely to present with a
recurrence when compared to Dukes’ B patients without allelic im-
balances (Zhou et al., 2002). Focal chromosomal CNAs have also been
implicated in prognosis of CRC patients. A study on 46 stage II CRC
concluded that loss of 5q34 was associated with worse OS and DFS and
gain of 13q.22.1 was associated with worse OS (Brosens et al., 2010).
Another study evaluated the effect of CNAs in a cohort (consisting of
89.1% MSS cases) of 302 stage II and III CRC patients with OS and
progression-free survival (Xie et al., 2012). Deletion at 10p15.3-p14
and 19p13.12 in both stages were associated with poor OS. Further-
more, deletions of 10p15.3-p14 were also significantly associated with
a worse RFS. On the contrary, in stage III patients, gain of 20q was
associated with better OS. At the chromosome-arm level, loss of chro-
mosome arm 4q (Brosens et al., 2011) and gain of chromosome arm 20q
(Aust et al., 2004) were associated with poor prognosis. Also, both 8q
gain and 20q gain were shown to be more frequently present in me-
tastasized tumors than in tumors without metastases (Buffart et al.,
2005; Hidaka et al., 2000).
5.3. Predictive biomarkers
Several CNAs have been associated with response to treatment in
CRC. TYMS amplification was investigated in a cohort of mCRC patients
treated with 5-fluorouracil (5-FU) based therapies, where it was asso-
ciated with resistance to 5-FU (Watson et al., 2010). On the contrary,
copy number deletion of the negative prognostic marker CD226 is as-
sociated with better OS following 5-FU-based therapy (Storojeva et al.,
2005). Buess and colleagues reported a study on stage II and III CRC
patients (n=166) and demonstrated that STRAP amplification results
in a worse response to 5-FU based therapy which was observed with the
patients having a higher relapse and death rate when compared to
patients without amplification (Buess et al., 2004a). In 2008, Postma
and colleagues carried out an investigation on CNA and response to
capecitabine plus irinotecan (XELIRI regimen), in a cohort of treatment-
naïve mCRC patients (n= 39). This study concluded that responders
showed loss of chromosomal bands 18p11.32-q11.2 and 18q12.1-q23
(Postma et al., 2009). In the KRAS wild-type mCRC sub-group, only
13–17% benefit from single-agent anti-EGFR therapy (Bertotti et al.,
2011). Additionally, in this sub-group increased EGFR copy numbers
are associated with improved response rates to irinotecan-cetuximab
therapy and longer time to progression (Scartozzi et al., 2009). Meta-
static CRC patients with EGFR amplifications as confirmed by FISH are
more likely to respond to monoclonal antibodies targeting EGFR
(Moroni et al., 2005). In 2013, Jiang and colleagues reported a meta-
analysis of 13 studies representing 1,174 mCRC patients treated with
either cetuximab or panitumumab. Their results showed that EGFR
copy number gains in this population were associated with improved
OS and PFS (Jiang et al., 2013).
The mechanisms to understand why KRAS amplification in mCRC
may be involved in resistance to EGFR-targeted therapies has been in-
vestigated (Valtorta et al., 2013). Yaeger and colleagues hypothesized
that RAS amplification in KRAS wild-type CRCs induces acquired re-
sistance to RAF inhibitors through the formation of drug-resistant RAF
dimers, although the authors recognized that more studies are required
to confirm this hypothesis (Yaeger et al., 2017). MET amplification is
more frequent in mCRC cases that have acquired resistance to anti-
EGFR therapy compared to de novo mCRC (Bardelli et al., 2013;
Pietrantonio et al., 2016). Therefore,METmay be an ideal on-treatment
monitoring candidate biomarker, especially since CNAs can be detected
in cfDNA (Raghav et al., 2016).
In addition to its role in breast cancer, HER2 amplification is an
emerging biomarker in advanced CRC. Sartore-Bianchi and colleagues
argued that KRAS exon 2 wild-type mCRCs should be tested for HER2
amplification because, in this sub-group of patients, HER2 amplifica-
tions may indicate responses to trastuzumab and pertuzumab; however,
KRAS-mutant patients may be intrinsically resistant to anti-HER2
therapy even in the presence of HER2 amplification (Sartore-Bianchi
et al., 2018). Therefore, the overall genetic context matters, and in-
dividual CNAs alone may not fully indicate the treatment response of a
particular tumor. In fact, Corcoran and colleagues reported BRAF am-
plification in a BRAF V600E mutated CRC and speculated that BRAF
amplification in this cohort might lead to acquired resistance to MEK
and BRAF inhibitors (Corcoran et al., 2010).
The presence of other specific CNAs has been associated with the
response to treatment in mCRC. In a comprehensive analysis of CNAs in
349 tumors resected from patients participating in the CAIRO and
CAIRO2 clinical trials, it was observed that specific chromosomal re-
gions, mainly gain of 6q and loss of 18q, were associated with sig-
nificant difference in progression-free survival (PFS) between treatment
arms with and without irinotecan (Haan et al., 2014). Furthermore, van
Dijk and colleagues recently reported that the loss of chromosome
18q11.2-q12.1 in mCRC patients was indicative of good prognosis as
these patients achieved prolonged PFS, better OS and better overall
response rate when receiving becacizumab (van Dijk et al., 2018). Si-
milarly, Smeets and colleagues investigated the likelihood of other
CNAs as candidate predictive biomarkers to guide therapy with bev-
acizumab in a cohort of mCRC patients (Smeets et al., 2018). In this
study, the authors took a novel approach, where initially they clustered
the CNA profiles of 908 CRC patients using unsupervised hierarchical
clustering, resulting in three different clusters. The first cluster was
characterized by tumors having a considerable amount of somatic
mutations, including tumors having POLE and POLD1 mutations and
MSI classified tumors. Additionally, this cluster had only 10.2% ad-
vanced CRC patients and presented with few CNAs when compared
with the other clusters. The authors proceeded with analyzing the re-
sponse of the mCRC cohort with respect to chemotherapy alone versus
chemotherapy in combination with bevacizumab. Patients in cluster 2
and 3 (intermediate to high instability) being administered che-
motherapy in combination with bevacizumab had a better PFS and OS
when compared to those receiving chemotherapy alone. On the other
hand, patients in cluster 1 did not benefit from the addition of bev-
acizumab. The authors proceeded with comparing the CNA-based
clusters to the current CMS classification system. CNA-based clusters
overlapped with CMS sub-types: cluster 1 (low CNAs) was akin to CMS1
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and 3, cluster 2 and 3 were similar to CMS 2 and 4. As a result, it was
concluded that in mCRC patients, copy number load might be a novel
predictive marker for the efficacy of bevacizumab combination therapy.
Besides gene dosage alterations, CIN can also lead to structural re-
arrangements, like breakpoints and translocations leading to fusions of
different genes. Kloosterman and collegaues, in a systematic analysis of
278 CRCs, identified several novel oncogenic gene fusions in CRC that
may drive malignant development and offer new targets for persona-
lized therapy (Kloosterman et al., 2017). Chromosomal breakpoints in
MACROD2, leading to loss of its expression, occurs frequently in ad-
vanced CRC (van den Broek et al., 2015). In addition, loss of expression
of MACROD2 was associated with poor prognosis in stage II and III
CRCs and with poor response to 5FU-based chemotherapy in stage III
CRCs (van den Broek et al., 2018).
6. Conclusions and future challenges
There is a positive correlation between genomic CNAs and resident
gene expression levels in cancer, resulting in a massive deregulation
affecting not only genes on aneuploid chromosomes but also genes
throughout the genome. This phenomenon is, naturally, associated with
the fact that CNAs are cancer-type specific, which defines aneuploidy-
dependent cancer type transcriptional programs. Taking this into con-
sideration, several questions arise: (i) are all genes residing on a chro-
mosome affected by such positive correlation or, alternatively, some
genes escape this dependency? (ii) to what extent are CNAs the result of
positively selected regions of the genome containing oncogenes and
tumor suppressor genes? (iii) are those gene expression networks de-
fined in carcinomas already functional in premalignant lesions? It re-
mains to be clarified how exactly aneuploidy shapes the transcriptome
of cancer cells and why cancer cells require such aneuploidy-specific
deregulated transcriptional networks.
From the clinical point of view, the translational significance of
genomic CNAs into clinical practice requires further studies.
Eventually, understanding CNAs will allow stratification of patients
based on biological and genetic features to improve disease prog-
nostication, follow-up and to guide therapeutic strategies.
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